摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,6-diamino-1,2,4,5-tetrazine | 19617-90-4

中文名称
——
中文别名
——
英文名称
3,6-diamino-1,2,4,5-tetrazine
英文别名
1,2,4,5-tetrazine-3,6-diamine
3,6-diamino-1,2,4,5-tetrazine化学式
CAS
19617-90-4
化学式
C2H4N6
mdl
MFCD00506758
分子量
112.094
InChiKey
JOYXTMYVRNWHNJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.1
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    104
  • 氢给体数:
    2
  • 氢受体数:
    6

SDS

SDS:e2d7e3c0d1a928914b7a4c596098af70
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3,6-diamino-1,2,4,5-tetrazine甲酸双氧水 作用下, 反应 1.0h, 以65%的产率得到3,6-diamino-1,2,4,5-tetrazine 1,4-dioxide
    参考文献:
    名称:
    3,6-二氨基-1,2,4,5-四嗪和3,6-双(s,s-二甲基磺基氨基)-1,2,4,5-四嗪的氧化
    摘要:
    用大多数过酸氧化3,6-二氨基-1,2,4,5-四嗪(1)得到3,6-二氨基-1,2,4,5-四嗪1,4-二氧化物(3)产品; 但是,用过氧三氟乙酸(PTFA)处理1会得到3,6-二氨基-1,2,4,5-四嗪1氧化物(4)作为主要产物,以及少量的3-氨基6-硝基-1,2,4,5-四嗪2,4-二氧化物(5)。用3-氯过氧苯甲酸(MCPBA)氧化3,6-双(S,S-二甲基亚砜基氨基)-1,2,4,5-四嗪(6)得到3- S,S-(二甲基亚砜基氨基)-6-亚硝基1,2,4,5-四嗪(7),将其进一步用二甲基二环氧乙烷氧化为3-(S,S-二甲基亚砜基亚氨基)-6-硝基-1,2,4,5-四嗪(8)。通过进一步氧化7或8获得3,6-二硝基-1,2,4,5-四嗪(2)的所有尝试均告失败。
    DOI:
    10.1002/jhet.5570300623
  • 作为产物:
    参考文献:
    名称:
    The Synthesis of sym-Diaminotetrazine1a,1b
    摘要:
    DOI:
    10.1021/ja01631a031
点击查看最新优质反应信息

文献信息

  • Synthesis of monosubstituted 1,2,4,5-tetrazines – 3-amino-1,2,4,5-tetrazines
    作者:Gennady F. Rudakov、Yurii A. Moiseenko、Natal’ya А. Spesivtseva
    DOI:10.1007/s10593-017-2127-4
    日期:2017.6
    The substitution of pyrazolyl moiety in 3-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine with N-nucleophiles provided a series of highnitrogen tetrazine derivatives, including 2-nitro-1-(1,2,4,5-tetrazin-3-yl)guanidine, N-(1H-tetrazol-5-yl)-1,2,4,5-tetrazin-3-amine, N-(1,2,4,5-tetrazin-3-yl)-1,2,4,5-tetrazin-3-amine, N,N'-di(1,2,4,5-tetrazin-3-yl)-1,2,4,5-tetrazine-3,6-diamine, N-(1,2,4,5-tetrazin-3-yl)-[1
    用N-亲核试剂取代3-(3,5-二甲基-1 H-吡唑-1-基)-1,2,4,5-四嗪中的吡唑基部分,提供了一系列高氮四嗪衍生物,包括2-硝基-1-(1,2,4,5-四嗪-3-基)胍,N-(1 H-四唑-5-基)-1,2,4,5-四嗪-3-胺,N-( 1,2,4,5-四嗪-3-基)-1,2,4,5-四嗪-3-胺,N,N'-二(1,2,4,5-四嗪-3-基) -1,2,4,5-四嗪-3,6-二胺,N-(1,2,4,5-四嗪-3-基)-[1,2,4]三唑[4,3- b ] [1,2,4,5]四嗪-6-胺和三四嗪胺。通过差示扫描量热法评估了这些新化合物的热稳定性,并计算了它们的能量特性。
  • Selective N1/N4 1,4-Cycloaddition of 1,2,4,5-Tetrazines Enabled by Solvent Hydrogen Bonding
    作者:Zixi Zhu、Christopher M. Glinkerman、Dale L. Boger
    DOI:10.1021/jacs.0c09775
    日期:2020.12.9
    survey of participating 1,2,4,5-tetrazines, and key mechanistic insights into this reaction are detailed. Given its simplicity and breath, the study establishes a novel method for the simple and efficient one-step synthesis of 1,2,4-triazines under mild conditions from readily accessible starting materials. Whereas alternative protic solvents (e.g., MeOH vs HFIP) provide products of the conventional
    描述了一种前所未有的 1,2,4,5-四嗪的 1,4-环加成(vs 3,6-环加成),其中预制或原位生成的芳基共轭烯胺由六氟异丙醇 (HFIP) 的溶剂氢键促进,即在温和的反应条件(0.1 M HFIP,25 °C,12 小时)下进行。该反应构成了 1,2,4,5-四嗪的两个氮原子 (N1/N4) 之间的正式 [4 + 2] 环加成,然后是腈的正式逆 [4 + 2] 环加成损失和芳构化生成 1,2,4-三嗪衍生物。影响反应模式显着变化的因素,反应参数的优化,通过醛和酮原位生成烯胺实现的范围和简化,3,6-双(硫甲基)-1,2的反应范围,4,5-四嗪, 参与调查 1,2, 详细介绍了 4,5-四嗪以及对该反应的关键机理见解。鉴于其简单性和呼吸性,该研究建立了一种新方法,可在温和条件下从容易获得的起始材料中简单有效地一步合成 1,2,4-三嗪。尽管替代质子溶剂(例如,MeOH 与 HFIP)提供了传统
  • COMPOSITIONS AND METHODS FOR DELIVERING A SUBSTANCE TO A BIOLOGICAL TARGET
    申请人:The General Hospital Corporation
    公开号:EP3622968A1
    公开(公告)日:2020-03-18
    The present application provides compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reaction for rapid and specific covalent delivery of a "payload" to a ligand bound to a biological target.
    本申请提供了一种使用生物正交反向电子需求Diels-Alder环加成反应的组合物和方法,用于快速和特异性地将“有效载荷”共价地传递给结合在生物靶点上的配体。
  • [EN] HETEROARYL DERIVATIVES OF FORMULA (I) AS ATF4 INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLES DE FORMULE (I) UTILISÉS EN TANT QU'INHIBITEURS D'ATF4
    申请人:GLAXOSMITHKLINE IP DEV LTD
    公开号:WO2019193540A1
    公开(公告)日:2019-10-10
    The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein A, C, D, L2, L3, R1, R2, R3, R4, R 5, R6, z2, z4, z5, and z6 are as defined herein; or salts thereof. The compounds of the invention are inhibitors of the ATF4 pathway and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt-Jakob Disease, and related prion diseases, progressive supranuclear palsy, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, inflammation, fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, chronic traumatic encephalopathy (CTE), neurodegeneration, dementia, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    该发明涉及取代杂环芳基衍生物。具体来说,该发明涉及符合以下式(I)的化合物,其中 A、C、D、L2、L3、R1、R2、R3、R4、R5、R6、z2、z4、z5 和 z6 如本文中所定义;或其盐。该发明的化合物是ATF4途径的抑制剂,可用于治疗癌症、癌前综合征以及与激活的未折叠蛋白反应途径相关的疾病,如阿尔茨海默病、脊髓损伤、创伤性脑损伤、缺血性中风、中风、糖尿病、帕金森病、亨廷顿病、克雅氏病、相关朊病、进行性核上性麻痹、肌萎缩侧索硬化、心肌梗死、心血管疾病、炎症、纤维化、肝脏慢性和急性疾病、肺部慢性和急性疾病、肾脏慢性和急性疾病、慢性创伤性脑病(CTE)、神经退行性疾病、痴呆、认知障碍、动脉粥样硬化、眼部疾病、心律失常、器官移植以及器官运输用于移植。因此,该发明还涉及包含该发明化合物的药物组合物。该发明还涉及使用该发明化合物或包含该发明化合物的药物组合物抑制ATF4途径和治疗相关疾病的方法。
  • 3-Amino-6-nitroamino-tetrazine (ANAT)-based energetic salts
    作者:Haixiang Gao、Ruihu Wang、Brendan Twamley、Michael A. Hiskey、Jean'ne M. Shreeve
    DOI:10.1039/b608214a
    日期:——
    The synthesis and properties of several new high-nitrogen materials with 3-amino-6-nitroamino-tetrazine (ANAT) as the anion are reported; all salts were fully characterized by IR and NMR spectroscopy, and elemental analysis.
    报告了几种以 3-amino-6-nitroamino-tetrazine (ANAT) 为阴离子的新型高氮材料的合成和特性;所有盐类都通过红外光谱、核磁共振光谱和元素分析进行了全面表征。
查看更多

同类化合物

酸四嗪 甲四嗪-氨基叔丁酯 四嗪-氨基叔丁酯 嘧啶并[4,5-e]-1,2,3,4-四嗪 二甲基-1,2,4,5-四嗪 二氯均四嗪 METHYLTETRAZINE-ACID,甲基四嗪-羧基 6-苯基-1,2,4,5-四嗪-3-胺 6-乙基-1,2,4,5-四嗪-3-胺 6-丁基氨基-3-(3,5-二甲基吡唑-1-基)四嗪 6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-胺 3,6-二苯基-1,2,4,5-四嗪 3,6-二氨基-1,2-二氢-1,2,4,5-四嗪盐酸盐 3,6-二-4-吡啶基-1,2,4,5-四嗪 3,6-二-2-吡啶基-1,2,4,5-四嗪 3,6-二(噻吩-2-基)-1,2,4,5-四嗪 3,6-二(3-吡啶基)-1,2,4,5-四氮杂苯 3,6-二(3,5-二甲基-1H-吡唑-1-基)-1,2,4,5-四嗪 1-[6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-基]-2-(丙-2-亚基)肼 1,2-二氢-1,2,4,5-四嗪-3,6-二酮 1,2,4,5]四嗪-3,6-二羧酸 1,2,4,5-四嗪-3-胺 1,2,4,5-四嗪-3,6-二羧酸二甲酯 1,2,4,5-四嗪 (9CI)-吡咯并[2,1-d]-1,2,3,5-四嗪 (6-肼基-1,2,4,5-四嗪-3-基)肼 3-(3,5-Dimethyl-1-pyrazolyl)-6-(2-trifluoroacetylhydrazino)-1,2,4,5-tetrazine 3-cyclohexyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-ethyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 6-pentyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-benzyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-methyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine N'-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-yl)propionohydrazide 3-(2-ethylidenehydrazinyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine (1,2,4,5-tetrazine-3,6-diyl)dimethanol 3-amino-6-chloro-1,2,4,5-tetrazine 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-methyl-1,2,4,5-tetrazin-3-amine N-(tert-butyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-amine 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-(prop-2-en-1-yl)-1,2,4,5-tetrazin-3-amine 3-(2-pyrimidyl)-6-(2-hydroxy)ethyl-1,2,4,5-tetrazine 3-isopropyl-6-phenyl-1,2,4,5-tetrazine 6-butylamino-3-chlorotetrazine 3,6-di(1H-pyrazol-4-yl)-1,2,4,5-tetrazine N-(1H-tetrazol-5-yl)-1,2,4,5-tetrazin-3-amine 3-(3,5-dimethylpyrazolyl)-6-[tris(hydroxylmethyl)aminomethane]-1,2,4,5-tetrazine 2-([1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-3-ylamino)-2-(hydroxymethyl)propane-1,3-diol 6-amino-1,2,4-triazolo<4,3-b><1,2,4,5>tetrazine N-phenethyl-[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-3-amine 2,5-dioxopyrrolidin-1-yl 2-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)acetate furazano-1,2,3,4-tetrazine 1,3-dioxide